The bioavailability of the active ingredient is a crucial factor in drug development, and although certain biomolecules possess intervening properties in organisms, their application is often limited by low bioavailability [61]. Low bioavailability is typically attributed to low water solubility or low me...
INEFFECTIVENESS OF ZINC GLUCONATE NASAL SPRAY AND ZINC OROTATE LOZENGES IN COMMON-COLD TREATMENT: A DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL. to shorten the duration of common colds in a dose-response manner when the amount of the active ingredient, positively charged zinc ions, is sufficient...
Overview of the different active ingredient classes and their free and fixed combinations Decongestants (α-sympathomimetics) For the acute treatment of AR, α sympathomimetics are used, which bind to and activate α‑adrenoreceptors. The result is a vasoconstriction of the nasal mucosa, which le...
PROCESS FOR PRODUCING NEW, NASALLY APPLICABLE GALENIC COMPOSITION COMPRISING OCTREOTIDE AS ACTIVE INGREDIENTNasal pharmaceutical compsn. contg. octreotide of formula (I) is new. The compsn. may be in the form of a liquid, e.g. an aq. soln., a nasal insert, a powder, e.g. particles ...
Spray‐dried chestnut extract containing Lactobacillus rhamnosus cells as novel ingredient for a probiotic chestnut mousse AimsConsumers' demand for innovative probiotic products has recently increased. In previous studies, chestnuts were evaluated as substrate for the growth o... A Romano,G Blaiotta,AD...
Lozenge #2, containing HR as active ingredient, was moderately antivirally active. In the case of HRV8, a member of the major group rhinoviruses, the by far largest group of rhinoviruses, we could confirm the findings of Oxford et al.5 None of the tested AMC/DCBA or HR containing ...
pseudoephedrine or phenylpropanolamine or a pharmaceutically acceptable salt or derivative thereof, and at least one other active ingredient selected from a non-steriodal anti-inflammatory, an anti-histamine, a local anaesthetic, an antiseptic anaesthetic and a cough suppressant, and a pharmaceutically ...
North America is the dominant region inactive pharmaceutical ingredient (API) marketduring the forecast period 2023 to 2030 North America dominates the active pharmaceutical ingredient (API) market owing to the well-established healthcare infrastructure and growing healthcare expenditures in this region. ...
In many embodiments, the active pharmaceutical ingredient comprises a pharmaceutically or active ingredient, excipient, or a mixture of two or more thereof. The active pharmaceutical ingredient may comprise one which is suitable for delivery by inhalation (which term includes nasal and/or oral inhalatio...
PROCESS FOR PRODUCING NEW, NASALLY APPLICABLE GALENIC COMPOSITION COMPRISING OCTREOTIDE AS ACTIVE INGREDIENTNasal pharmaceutical compsn. contg. octreotide of formula (I) is new. The compsn. may be in the form of a liquid, e.g. an aq. soln., a nasal insert, a powder, e.g. particles ...